These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31656119)

  • 1. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry.
    Pastori D; Antonucci E; Violi F; Palareti G; Pignatelli P; ;
    J Am Heart Assoc; 2019 Nov; 8(21):e012596. PubMed ID: 31656119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry.
    Li YG; Miyazawa K; Wolff A; Zubaid M; Alsheikh-Ali AA; Sulaiman K; Lip GYH
    Int J Cardiol; 2019 Jan; 274():158-162. PubMed ID: 30291008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
    Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A
    J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study.
    Potpara TS; Polovina MM; Marinkovic JM; Lip GY
    Int J Cardiol; 2013 Oct; 168(5):4744-9. PubMed ID: 23958417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase.
    Proietti M; Laroche C; Nyvad O; Haberka M; Vassilikos VP; Maggioni AP; Boriani G; Lip GYH;
    Int J Cardiol; 2017 Dec; 248():166-172. PubMed ID: 28859841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.
    Wang CL; Wu VC; Lee CH; Kuo CF; Chen YL; Chu PH; Chen SW; Wen MS; See LC; Chang SH
    J Thromb Thrombolysis; 2019 May; 47(4):512-519. PubMed ID: 30565148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry.
    Bertomeu-Gonzalez V; Moreno-Arribas J; Esteve-Pastor MA; Roldán-Rabadán I; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    J Am Heart Assoc; 2020 Jan; 9(1):e013789. PubMed ID: 31870235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry.
    Haeusler KG; Tütüncü S; Kunze C; Schurig J; Malsch C; Harder J; Wiedmann S; Dimitrijeski B; Ebinger M; Hagemann G; Hamilton F; Honermann M; Jungehulsing GJ; Kauert A; Koennecke HC; Leithner C; Mackert BM; Masuhr F; Nabavi D; Rocco A; Schmehl I; Schmitz B; Sparenberg P; Stingele R; von Brevern M; Völzke E; Dietzel J; Heuschmann PU; Endres M
    Europace; 2019 Nov; 21(11):1621-1632. PubMed ID: 31397475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry.
    Boriani G; Laroche C; Diemberger I; Fantecchi E; Popescu MI; Rasmussen LH; Dan GA; Kalarus Z; Tavazzi L; Maggioni AP; Lip GY
    Europace; 2016 May; 18(5):648-57. PubMed ID: 26826133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
    Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
    Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry.
    Esato M; Chun YH; An Y; Ogawa H; Wada H; Hasegawa K; Tsuji H; Abe M; Lip GYH; Akao M
    Chest; 2017 Dec; 152(6):1266-1275. PubMed ID: 28823813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention.
    Kiviniemi T; Karjalainen P; Rubboli A; Schlitt A; Tuomainen P; Niemelä M; Laine M; Biancari F; Lip GY; Airaksinen KE
    Am J Cardiol; 2013 Aug; 112(4):493-8. PubMed ID: 23672991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
    Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.